Ad
related to: kidney transplant acute rejection
Search results
Results From The WOW.Com Content Network
Acute rejection is a category of rejection that occurs on the timescale of weeks to months, with most episodes occurring within the first 3 months to 1 year after transplantation. [ 6 ] [ 8 ] Unlike hyperacute rejection, acute rejection is thought to arise from two distinct immunological mechanisms as lymphocytes , a subset of white blood cells ...
Acute rejection is another possible complication of kidney transplantation; it is graded according to the Banff Classification which incorporates various serologic, molecular and histologic markers to determine the severity of the rejection. Acute rejection can be classified as T-cell mediated, antibody mediated or both (mixed rejection).
Anti-thymocyte globulin (ATG) is an infusion of horse or rabbit-derived antibodies against human T cells and their precursors , which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia due to bone marrow insufficiency.
A novel approach to organ transplantation allowed patients to wean off anti-rejection drugs after two years, according to the results of a phase 3 clinical trial presented Monday.
Thymoglobulin is commonly used to prevent and treat acute rejection and increase graft survival in solid organ transplantation (SOT), especially kidney, liver, pancreas, and heart transplantation. [1]
Basiliximab is indicated for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation. [3] It is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in people with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids ...
Muromonab-CD3 is approved for the therapy of acute, glucocorticoid-resistant rejection of allogeneic kidney, heart, and liver transplants. [4] Unlike the monoclonal antibodies basiliximab and daclizumab, it is not approved for prophylaxis of transplant rejection, although a 1996 review has found it to be safe for that purpose.
Samuel Lee Kountz Jr. (October 30, 1930 – December 23, 1981) was an African-American kidney transplantation surgeon from Lexa, Arkansas.He was most distinguished for his pioneering work in the field of kidney transplantations, and in research, discoveries, and inventions in Renal Science.